Clinical Trials Logo

Large B-cell Lymphoma clinical trials

View clinical trials related to Large B-cell Lymphoma.

Filter by:

NCT ID: NCT06375733 Recruiting - Clinical trials for Large B-cell Lymphoma

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Start date: March 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

NCT ID: NCT06356129 Not yet recruiting - Clinical trials for Large B-cell Lymphoma

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

GOLSEEK-1
Start date: June 24, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).

NCT ID: NCT06343311 Not yet recruiting - Lymphoma Clinical Trials

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Starlight-1
Start date: May 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.

NCT ID: NCT06285422 Not yet recruiting - Clinical trials for Large B-cell Lymphoma

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID)

Start date: April 2024
Phase: Phase 1
Study type: Interventional

SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

NCT ID: NCT06167785 Not yet recruiting - Clinical trials for Large B-cell Lymphoma

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

ZanTisle
Start date: August 2024
Phase: Phase 2
Study type: Interventional

This is a phase ll study of participants with large B Cell lymphoma previously treated with anti-CD19 Chimeric antigen receptor (CAR-T) therapy. The purpose of the study is to to evaluate the efficacy of zanubrutinib and tislelizumab in patients with progressive lymphoma post anti-CD 19 CAR-T failure.

NCT ID: NCT06142188 Not yet recruiting - Follicular Lymphoma Clinical Trials

Relmacabtagene Autoleucel in Hematologic Malignancies

Start date: December 28, 2023
Phase:
Study type: Observational

To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world

NCT ID: NCT06142175 Recruiting - Clinical trials for Large B-cell Lymphoma

Relmacabtagene Autoleucel in Patients With LBCL

Start date: December 28, 2022
Phase:
Study type: Observational

To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world

NCT ID: NCT06104592 Recruiting - Clinical trials for Large B-cell Lymphoma

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Start date: November 8, 2023
Phase: Phase 2
Study type: Interventional

This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.

NCT ID: NCT06071871 Not yet recruiting - Clinical trials for Large B-cell Lymphoma

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

PORTAL
Start date: April 30, 2024
Phase: Phase 2
Study type: Interventional

The PORTAL study will test a new combination of drugs (glofitamab, polatuzumab vedotin and obinutuzumab) in patients with large B-cell lymphoma (LBCL) that has come back (relapsed) or not responded to previous treatment. It will determine how safe and effective the combination of these cancer drugs is in treating LBCL before and after CAR-T cell therapy.

NCT ID: NCT06047080 Recruiting - Clinical trials for Large B-Cell Lymphoma

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Start date: September 18, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).